Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Celldex Therapeutics, Inc (CLDX)

In Vitro & In Vivo Diagnostic Substances

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/26/1990

Market Cap

2,241,846,632

Shares Outstanding

54,690,000

Weighted SO

54,689,197

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

IDYA --.--%

ANAB --.--%

MGTX --.--%

KROS --.--%

FIXX --.--%

CERE --.--%

RNA --.--%

RVMD --.--%

DAWN --.--%

Beta

1.5780

Last Div

0.0000

Range

22.11-53.18

Chg

0.7200

Avg Vol

711837

Mkt Cap

2241846632

Exch

NASDAQ

Country

US

Phone

908 200 7500

DCF Diff

38.6708

DCF

-5.1508

Div Yield

0.0000

P/S

270.0369

EV Multiple

-13.4919

P/FV

2.7441

Div Yield %

0.0000

P/E

-14.8637

PEG

-0.5244

Payout

0.0000

Current Ratio

29.3577

Quick Ratio

29.3577

Cash Ratio

1.5453

DSO

278.4763

DIO

0.0000

Op Cycle

278.4763

DPO

447.9438

CCC

-169.4676

Gross Margin

0.6268

Op Margin

-19.6689

Pretax Margin

-18.0940

Net Margin

-18.0940

Eff Tax Rate

-0.0741

ROA

-0.1776

ROE

-0.2581

ROCE

-0.1996

NI/EBT

1.0000

EBT/EBIT

0.9199

EBIT/Rev

-19.6689

Debt Ratio

0.0028

D/E

0.0029

LT Debt/Cap

0.0010

Total Debt/Cap

0.0029

Int Coverage

-52.5051

CF/Debt

-50.9396

Equity Multi

1.0392

Rec Turnover

1.3107

Pay Turnover

0.8148

Inv Turnover

0.0000

FA Turnover

1.3149

Asset Turnover

0.0098

OCF/Share

-1.8402

FCF/Share

-1.8621

Cash/Share

12.0801

OCF/Sales

-14.6339

FCF/OCF

1.0119

CF Coverage

-50.9396

ST Coverage

-76.4575

CapEx Coverage

-84.3102

Div&CapEx Cov

-84.3102

P/BV

2.7441

P/B

2.7441

P/S

270.0369

P/E

-14.8637

P/FCF

-18.2365

P/OCF

-18.3780

P/CF

-18.3780

PEG

-0.5244

P/S

270.0369

EV Multiple

-13.4919

P/FV

2.7441

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 14, 14:48 Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 GlobeNewswire Inc. Mar 01, 17:45 Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 GlobeNewswire Inc. Oct 26, 21:43 Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out

Revenue Product Segmentation